AMG National Trust Bank Has $3.57 Million Position in Amgen Inc. $AMGN

Key Points

• AMG National Trust Bank cut its Amgen stake by 24.4% in the second quarter, selling 3,180 shares and retaining 9,854 shares valued at approximately $3.57 million. Institutional investors and hedge funds collectively own 76.5% of Amgen.
• Amgen reported strong quarterly results, with EPS of $6.29 beating estimates of $5.62 and revenue rising 9.5% year over year to $10.05 billion. The company issued fiscal 2026 EPS guidance of $22.30–$23.50.
• Amgen declared a quarterly dividend of $2.52 per share, equivalent to an annualized $10.08 and a 2.4% yield. Despite recent analyst target increases, the stock’s consensus rating remains “Hold,” with an average price target of $375.93.

AMG National Trust Bank lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 24.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,854 shares of the medical research company's stock after selling 3,180 shares during the period. AMG National Trust Bank's holdings in Amgen were worth $3,568,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. Anfield Capital Management LLC increased its holdings in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock valued at $25,000 after buying an additional 70 shares during the period. Dogwood Wealth Management LLC lifted its holdings in shares of Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock worth $25,000 after acquiring an additional 55 shares during the period. Tower View Wealth Management LLC boosted its position in shares of Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock worth $29,000 after acquiring an additional 63 shares in the last quarter. Manning & Napier Advisors LLC boosted its position in shares of Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock worth $32,000 after acquiring an additional 32 shares in the last quarter. Finally, Ares Financial Consulting LLC bought a new position in Amgen in the fourth quarter valued at approximately $34,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Up 1.4%

Shares of AMGN opened at $425.28 on Wednesday. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $427.39. The stock has a market capitalization of $229.92 billion, a price-to-earnings ratio of 26.43, a PEG ratio of 3.86 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The stock has a fifty day moving average of $373.66 and a 200-day moving average of $360.06.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping analysts' consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The business had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same quarter in the previous year, the company posted $6.02 EPS. Amgen's quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.78 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Friday, August 21st. Amgen's dividend payout ratio (DPR) is presently 62.65%.

Insider Activity

In related news, SVP Rachna Khosla sold 1,252 shares of the firm's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 6,222 shares of company stock worth $2,540,926. Company insiders own 0.85% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on AMGN. TD Cowen upped their target price on Amgen from $420.00 to $452.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Argus lowered their price target on Amgen from $400.00 to $375.00 and set a "buy" rating for the company in a report on Wednesday, May 20th. Wells Fargo & Company upped their price objective on Amgen from $390.00 to $400.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 5th. Sanford C. Bernstein lifted their target price on Amgen from $335.00 to $345.00 and gave the company a "market perform" rating in a research report on Thursday, August 6th. Finally, Wall Street Zen raised Amgen from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $375.93.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s recent results reinforced its growth narrative: quarterly revenue rose 9.5% year over year to $10.05 billion, while adjusted earnings of $6.29 per share exceeded consensus by $0.67. Management’s fiscal 2026 EPS guidance of $22.30–$23.50 also supports the bullish outlook. Amgen Results Put Growth Back in Focus
• Positive Sentiment: A completed Phase 1 study comparing two evolocumab formulations provides continued support for Amgen’s cholesterol franchise. Evolocumab, marketed as Repatha, is an important commercial product, and formulation work could help support its future development and patient use. Amgen’s Evolocumab Formulation Study
• Positive Sentiment: Growth-focused analysis from Zacks highlights Amgen’s earnings profile and potential for continued performance, adding to the favorable investor narrative. Why Amgen Is a Strong Growth Stock
• Neutral Sentiment: Cantor Fitzgerald raised its Amgen price target to $400 but retained a Neutral rating. Mizuho also maintained Neutral while lifting its target to $352, indicating that analysts see some fundamental improvement but believe the recent rally has exceeded their valuation expectations.
• Negative Sentiment: Amgen exercised its right to terminate a partnership with TScan Therapeutics, removing a collaboration from TScan’s pipeline. While the direct financial effect on Amgen is unclear, the termination may raise questions about partnership prioritization or the development prospects of the related program. TScan Therapeutics Faces Loss of Key Amgen Partnership

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source